vs
AGENUS INC（AGEN）与AIM ImmunoTech Inc.（AIM）财务数据对比。点击上方公司名可切换其他公司
AGENUS INC的季度营收约是AIM ImmunoTech Inc.的1628.8倍（$34.2M vs $21.0K）。AGENUS INC净利率更高（-31.0% vs -19881.0%，领先19849.9%）。AGENUS INC同比增速更快（27.5% vs -53.3%）。过去两年AGENUS INC的营收复合增速更高（10.5% vs -27.5%）
Agenus Inc.是一家总部位于美国马萨诸塞州列克星敦的生物技术公司，核心业务聚焦免疫治疗领域，尤其专注于利用人体免疫系统控制或治愈癌症的肿瘤免疫治疗。公司目前正在研发检查点调节剂、个性化抗癌疫苗，以及可适配多种疫苗的免疫佐剂，其中检查点调节剂作为当前进展迅速的方向，早期产品已为患者带来突破性临床获益。
AIM ImmunoTech是一家总部位于美国佛罗里达州奥卡拉的生物制药企业，前身是Hemispherx Biopharma，1990年成立，目前专注于研发用于治疗多种癌症、各类病毒感染以及免疫缺陷疾病的创新疗法。
AGEN vs AIM — 直观对比
营收规模更大
AGEN
是对方的1628.8倍
$21.0K
营收增速更快
AGEN
高出80.8%
-53.3%
净利率更高
AGEN
高出19849.9%
-19881.0%
两年增速更快
AGEN
近两年复合增速
-27.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $34.2M | $21.0K |
| 净利润 | $-10.6M | $-4.2M |
| 毛利率 | — | — |
| 营业利润率 | 42.1% | -14057.1% |
| 净利率 | -31.0% | -19881.0% |
| 营收同比 | 27.5% | -53.3% |
| 净利润同比 | 77.3% | 30.0% |
| 每股收益（稀释后） | $0.09 | $-6.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGENAIM
| Q4 25 | $34.2M | $21.0K | ||
| Q3 25 | $30.2M | $26.0K | ||
| Q2 25 | $25.7M | $25.0K | ||
| Q1 25 | $24.1M | $16.0K | ||
| Q4 24 | $26.8M | $45.0K | ||
| Q3 24 | $25.1M | $35.0K | ||
| Q2 24 | $23.5M | $50.0K | ||
| Q1 24 | $28.0M | $40.0K |
净利润AGENAIM
| Q4 25 | $-10.6M | $-4.2M | ||
| Q3 25 | $63.9M | $-3.3M | ||
| Q2 25 | $-30.0M | $-2.8M | ||
| Q1 25 | $-26.4M | $-3.7M | ||
| Q4 24 | $-46.8M | $-6.0M | ||
| Q3 24 | $-67.2M | $-3.7M | ||
| Q2 24 | $-54.8M | $-1.8M | ||
| Q1 24 | $-63.5M | $-5.8M |
毛利率AGENAIM
| Q4 25 | — | — | ||
| Q3 25 | 97.9% | — | ||
| Q2 25 | 99.1% | — | ||
| Q1 25 | 99.4% | — | ||
| Q4 24 | 99.6% | — | ||
| Q3 24 | 99.4% | — | ||
| Q2 24 | 99.5% | — | ||
| Q1 24 | 99.6% | — |
营业利润率AGENAIM
| Q4 25 | 42.1% | -14057.1% | ||
| Q3 25 | -15.0% | -9411.5% | ||
| Q2 25 | -65.0% | -10584.0% | ||
| Q1 25 | -55.3% | -22618.8% | ||
| Q4 24 | -96.5% | -13011.1% | ||
| Q3 24 | -125.5% | -12825.7% | ||
| Q2 24 | -128.4% | -7388.0% | ||
| Q1 24 | -117.4% | -14335.0% |
净利率AGENAIM
| Q4 25 | -31.0% | -19881.0% | ||
| Q3 25 | 211.4% | -12630.8% | ||
| Q2 25 | -116.8% | -11176.0% | ||
| Q1 25 | -109.6% | -23156.3% | ||
| Q4 24 | -174.4% | -13260.0% | ||
| Q3 24 | -267.7% | -10571.4% | ||
| Q2 24 | -233.1% | -3672.0% | ||
| Q1 24 | -226.6% | -14542.5% |
每股收益（稀释后）AGENAIM
| Q4 25 | $0.09 | $-6.46 | ||
| Q3 25 | $1.94 | $1.57 | ||
| Q2 25 | $-1.00 | $-3.68 | ||
| Q1 25 | $-1.03 | $-0.05 | ||
| Q4 24 | $-1.95 | $-21.80 | ||
| Q3 24 | $-3.08 | $-6.00 | ||
| Q2 24 | $-2.52 | $-3.00 | ||
| Q1 24 | $-3.04 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $3.0M |
| 总债务越低越好 | $44.7M | $4.5M |
| 股东权益账面价值 | $-271.1M | $-9.8M |
| 总资产 | $226.8M | $5.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AGENAIM
| Q4 25 | $3.0M | $3.0M | ||
| Q3 25 | $3.5M | $2.4M | ||
| Q2 25 | $9.5M | $835.0K | ||
| Q1 25 | $18.5M | $2.2M | ||
| Q4 24 | $40.4M | $4.0M | ||
| Q3 24 | $44.8M | $7.2M | ||
| Q2 24 | $93.7M | $10.1M | ||
| Q1 24 | $52.9M | $10.9M |
总债务AGENAIM
| Q4 25 | $44.7M | $4.5M | ||
| Q3 25 | $34.2M | — | ||
| Q2 25 | $33.9M | $2.7M | ||
| Q1 25 | $33.6M | $2.4M | ||
| Q4 24 | $33.2M | $2.8M | ||
| Q3 24 | — | $3.3M | ||
| Q2 24 | — | $3.3M | ||
| Q1 24 | — | $3.3M |
股东权益AGENAIM
| Q4 25 | $-271.1M | $-9.8M | ||
| Q3 25 | $-274.1M | $-6.1M | ||
| Q2 25 | $-354.6M | $-6.5M | ||
| Q1 25 | $-341.8M | $-3.9M | ||
| Q4 24 | $-326.4M | $-1.3M | ||
| Q3 24 | $-292.3M | $2.9M | ||
| Q2 24 | $-241.3M | $6.1M | ||
| Q1 24 | $-201.4M | $4.8M |
总资产AGENAIM
| Q4 25 | $226.8M | $5.8M | ||
| Q3 25 | $233.9M | $5.5M | ||
| Q2 25 | $185.2M | $4.1M | ||
| Q1 25 | $200.2M | $6.2M | ||
| Q4 24 | $226.3M | $8.6M | ||
| Q3 24 | $238.5M | $13.6M | ||
| Q2 24 | $292.4M | $15.7M | ||
| Q1 24 | $256.6M | $16.2M |
负债/权益比AGENAIM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.13× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.6M | $-2.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AGENAIM
| Q4 25 | $-16.6M | $-2.0M | ||
| Q3 25 | $-14.7M | $-5.1M | ||
| Q2 25 | $-20.2M | $-1.5M | ||
| Q1 25 | $-25.6M | $-2.4M | ||
| Q4 24 | $-28.7M | $-4.0M | ||
| Q3 24 | $-53.3M | $-3.1M | ||
| Q2 24 | $-38.2M | $-3.0M | ||
| Q1 24 | $-38.2M | $-4.8M |
自由现金流AGENAIM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-20.2M | — | ||
| Q1 25 | $-25.6M | — | ||
| Q4 24 | $-28.7M | — | ||
| Q3 24 | $-53.3M | — | ||
| Q2 24 | $-38.6M | — | ||
| Q1 24 | $-38.2M | — |
自由现金流率AGENAIM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -78.7% | — | ||
| Q1 25 | -106.5% | — | ||
| Q4 24 | -107.0% | — | ||
| Q3 24 | -212.2% | — | ||
| Q2 24 | -164.4% | — | ||
| Q1 24 | -136.5% | — |
资本支出强度AGENAIM
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 0.1% | — |
现金转化率AGENAIM
| Q4 25 | — | — | ||
| Q3 25 | -0.23× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
